Active — Not RecruitingPhase 2

Repeat or Single Quadratus Lumborum Block for the Reduction of Opioid Prescriptions After Surgery in Retroperitoneal Sarcoma Patients ("RESQU-SARC" Trial)

United States113 participantsStarted 2020-06-08

Plain-language summary

This phase II trial studies how well a repeat or single liposomal bupivacaine injection (quadratus lumborum block) works in reducing opioid prescriptions after surgery in patients with retroperitoneal sarcoma. Liposomal bupivacaine is a numbing medication. Giving a second injection block may decrease dependency on opioid medications for pain relief after surgery and prevent long-term use and addiction.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients undergoing elective open sarcoma resection for potentially curative intent who would otherwise be treated with quadratus lumborum (QL) block + intravenous-patient controlled analgesia (IV-PCA) converted to oral pain medications (meds) (non-narcotic bundle + opioid pain pill) Exclusion Criteria: * Patients with current or past substance (drug or alcohol) abuse disorder * Laparoscopic or minimally invasive surgery * Cases in which anticipated discharge is on or before postoperative day 4

What they're measuring

Initial Discharge Prescription Oral Morphine Equivalents (OME)

Timeframe: At time of discharge (median of 9 days)

Trial details

NCT IDNCT04189783

SponsorM.D. Anderson Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-10-26

Results submitted2025-09-24

View on ClinicalTrials.gov More Retroperitoneal Sarcoma trials